Evidence map›Paper›PMID 26611425›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2016

Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.

Ryogo Minamimoto, Amer Karam, Mehran Jamali, Amir Barkhodari, Sanjiv Sam Gambhir, Oliver Dorigo, Andrei Iagaru

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01806675 (Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01806675 phase1 / phase2completednot on this map

Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis

TypeinterventionalSponsorSanjiv Sam GambhirRan2013 to 2019Enrolled25ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast CancerArms18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Pretreatment PET/CT imaging of angiogenesis based onEuropean journal of nuclear medicine and molecular imaging · 2019
    Trial
  3. Review
  4. Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025
    Review
  5. EGFR- and Integrin αInternational journal of molecular sciences · 2024
    Review
  6. Review
  7. Review
  8. First-in-Human Study of [Diagnostics (Basel, Switzerland) · 2022
    Article
  9. PotentialFrontiers in oncology · 2022
    Article
  10. Review
  11. Evaluation of a CD13 and Integrin αFrontiers in oncology · 2022
    Article
  12. Review
  13. Frontiers in oncology · 2021
    Article
  14. Review
  15. Journal of nanobiotechnology · 2019
    Article
  16. European journal of nuclear medicine and molecular imaging · 2019
    Article
  17. Inter-heterogeneity and intra-heterogeneity of αEuropean journal of nuclear medicine and molecular imaging · 2017
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ryogo MinamimotoDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Amer KaramDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University, Stanford, CA, USA.
Mehran JamaliDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Amir BarkhodariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Sanjiv Sam GambhirDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Oliver DorigoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University, Stanford, CA, USA.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe report the effect of antiangiogenic therapy on the biodistribution of (18)F-FPPRGD2 (a surrogate biomarker of integrin αvβ3 expression), and the potential of (18)F-FPPRGD2 to predict the prognosis in patients with cervical cancer and ovarian cancer in this clinical scenario.

methodsData from six women, age range 30 - 59 years (mean ± SD 44.0 ± 12.5 years), who had undergone a (18)F-FPPRGD2 PET/CT scan and bevacizumab-containing therapy were prospectively collected and analyzed. We compared baseline (18)F-FPPRGD2 and (18)F-FDG uptake in the lesions and tumor-to-background (T/B) ratios. The maximum and mean (18)F-FPPRGD2 standardized uptake values (SUVmax and SUVmean) were recorded for 13 normal organs, as well as in all the identified malignant lesions on the pretreatment scan and the 1-week post-treatment scan. We also measured changes in (18)F-FPPRGD2 uptake from before to 1 week after treatment, and compared them to the changes in (18)F-FDG uptake from before to 6 weeks after treatment. Treatment outcomes were correlated with these changes.

resultsThe uptake in lesions and T/B ratio of (18)F-FPPRGD2 were lower than those of (18)F-FDG (SUVmax 3.7 ± 1.3 vs. 6.0 ± 1.8, P < 0.001; SUVmean 2.6 ± 0.7 vs. 4.2 ± 1.3, P < 0.001; T/B ratio based on SUVmax 2.4 ± 1.0 vs. 2.6 ± 1.0, P < 0.04; T/B ratio based on SUVmean 1.9 ± 0.6 vs. 2.4 ± 1.0, P < 0.003). One patient did not return for the follow-up scan and in another patient no lesions were identified on the pretreatment scan. (18)F-FPPRGD2 uptake in lesions in the remaining four patients had significantly changed 1 week after treatment (SUVmean 3.3 ± 1.0 vs. 2.7 ± 1.0, P < 0.001), while uptake in all normal tissues analyzed was not affected by treatment. One patient with clinical disease progression had a decrease in lesional (18)F-FPPRGD2 SUVmean of 1.6 % and in (18)F-FDG SUVmean of 9.4 %. Two patients with a clinical complete response to treatment had decreases in lesional (18)F-FPPRGD2 SUVmean of 25.2 % and 25.0 % and in (18)F-FDG SUVmean of 6.1 % and 71.8 %. One patient with a clinical partial response had a decrease in lesional (18)F-FPPRGD2 SUVmean of 7.9 % and in (18)F-FDG SUVmean of 76.4 %.

conclusionThis pilot study showed that (18)F-FPPRGD2 and (18)F-FDG provide independent information about the biology of ovarian and cervical cancers. Bevacizumab-containing therapy does not affect (18)F-FPPRGD2 uptake in normal organs, but does result in statistically significant changes in lesions. In addition, (18)F-FPPRGD2 may have potential for early prediction of response to such treatments. These preliminary findings have to be confirmed in larger studies.

Indexed as

Peptides, CyclicPositron Emission Tomography Computed TomographyAdultBiological TransportFemaleHumansMiddle AgedNeovascularization, PathologicOvarian NeoplasmsPilot ProjectsTreatment OutcomeUterine Cervical NeoplasmsFPP(RGD)2Peptides, Cyclic18F-FPPRGD2 PET/CTBevacizumabCervical cancerOvarian cancer

Identifiers

PMID26611425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.